glp-1 muscle loss Balancing weight and in GLP1 receptor agonist therapy The Muscle Loss Conversation No
Description
You cannot overwrite this file

doi: 10.1080/09546634.2020.1826392

Up-regulation of peroxisome proliferator-activated receptors (PPAR) and PPAR messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-responsive adipose tissue-specific genes in the liver of obese diabetic mice

GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight/obesity

10.1016/j.isci.2023.107680 [DOI] [PMC free article] [PubMed] [Google Scholar] Wei L., Mo W., Lan S., Yang H., Huang Z., Liang X., et al
Nissen, who serves as study co-chair of SURMOUNT-MMO, notes that the exclusion of patients with diabetes will avoid confounding of results by favorable outcomes due to tirzepatides antidiabetic effects
